TRUBION FINISHES ENROLLING PATIENTS IN RA STUDY

Trubion Pharmaceuticals announced it has completed enrollment and dosing of patients in its Phase IIb clinical trial of TRU-015, the company's lead Small Modular ImmunoPharmaceutical (SMIP) drug candidate for the treatment of rheumatoid arthritis (RA). The randomized, double-blind, placebo-controlled clinical trial is designed to evaluate safety and clinical response rates in patients with RA.

The Phase IIb randomized, double-blind, placebo-controlled clinical trial is designed to enroll 280 patients. Patients have been randomized into five groups to evaluate the safety and efficacy of an infused dose of TRU-015 compared with placebo for a 24-week period. Building on the findings of Trubion's Phase IIa clinical trial, this trial will evaluate the effect of a single infusion of TRU-015 ranging from 200 mg to 1,600 mg per patient.

Similar to the Phase IIa study, this study will evaluate composite measurements of improvement in disease activity derived from parameters such as tender and swollen joint counts, patient and physician global assessments, patient assessment of pain and disabilit, and laboratory measures of inflammation as defined by the American College of Rheumatology.

Trubion and Wyeth Pharmaceuticals are co-developing TRU-015, a SMIP drug candidate. SMIP drugs represent a novel class of immunotherapeutics that Trubion believes possess enhanced drug properties over monoclonal and recombinant antibodies.